Exagen (XGN) Competitors $4.20 +0.67 (+18.98%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends XGN vs. LFMD, SERA, BDSX, EUDA, QIPT, PIII, ENZ, BNR, MRAI, and CCMShould you be buying Exagen stock or one of its competitors? The main competitors of Exagen include LifeMD (LFMD), Sera Prognostics (SERA), Biodesix (BDSX), EUDA Health (EUDA), Quipt Home Medical (QIPT), P3 Health Partners (PIII), Enzo Biochem (ENZ), Burning Rock Biotech (BNR), Marpai (MRAI), and Concord Medical Services (CCM). These companies are all part of the "healthcare" industry. Exagen vs. LifeMD Sera Prognostics Biodesix EUDA Health Quipt Home Medical P3 Health Partners Enzo Biochem Burning Rock Biotech Marpai Concord Medical Services LifeMD (NASDAQ:LFMD) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership, community ranking and dividends. Is LFMD or XGN more profitable? LifeMD has a net margin of -12.06% compared to Exagen's net margin of -30.36%. LifeMD's return on equity of 0.00% beat Exagen's return on equity.Company Net Margins Return on Equity Return on Assets LifeMD-12.06% N/A -36.34% Exagen -30.36%-92.58%-33.74% Which has more risk and volatility, LFMD or XGN? LifeMD has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Comparatively, Exagen has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Do analysts rate LFMD or XGN? LifeMD currently has a consensus price target of $12.00, indicating a potential upside of 121.40%. Exagen has a consensus price target of $7.00, indicating a potential upside of 66.67%. Given LifeMD's higher probable upside, analysts clearly believe LifeMD is more favorable than Exagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LifeMD 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Exagen 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, LFMD or XGN? LifeMD has higher revenue and earnings than Exagen. LifeMD is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLifeMD$193.06M1.22-$20.60M-$0.64-8.47Exagen$52.55M1.41-$23.69M-$0.94-4.47 Does the media refer more to LFMD or XGN? In the previous week, Exagen had 12 more articles in the media than LifeMD. MarketBeat recorded 15 mentions for Exagen and 3 mentions for LifeMD. LifeMD's average media sentiment score of 0.87 beat Exagen's score of 0.84 indicating that LifeMD is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LifeMD 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exagen 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of LFMD or XGN? 35.5% of LifeMD shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 16.0% of LifeMD shares are held by company insiders. Comparatively, 26.1% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community prefer LFMD or XGN? LifeMD received 13 more outperform votes than Exagen when rated by MarketBeat users. Likewise, 75.56% of users gave LifeMD an outperform vote while only 55.26% of users gave Exagen an outperform vote. CompanyUnderperformOutperformLifeMDOutperform Votes3475.56% Underperform Votes1124.44% ExagenOutperform Votes2155.26% Underperform Votes1744.74% SummaryLifeMD beats Exagen on 10 of the 17 factors compared between the two stocks. Ad Angel PublishingTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.Click here to get the details. Get Exagen News Delivered to You Automatically Sign up to receive the latest news and ratings for XGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XGN vs. The Competition Export to ExcelMetricExagenMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$74.09M$2.98B$5.00B$8.81BDividend YieldN/A10.90%5.21%4.07%P/E Ratio-4.4716.50130.6617.50Price / Sales1.41257.891,201.6989.08Price / CashN/A373.0033.4132.51Price / Book5.754.924.684.68Net Income-$23.69M-$32.86M$118.04M$225.43M7 Day Performance52.73%-0.37%-2.44%-2.04%1 Month Performance45.83%-1.79%-4.03%0.04%1 Year Performance169.23%24.55%29.54%24.47% Exagen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XGNExagen4.7894 of 5 stars$4.20+19.0%$7.00+66.7%+169.2%$62.26M$52.55M-4.47220Analyst RevisionGap UpHigh Trading VolumeLFMDLifeMD2.3071 of 5 stars$5.42-2.5%$12.00+121.4%-23.7%$234.75M$193.06M-8.47230SERASera Prognostics1.0479 of 5 stars$6.03-2.4%N/A+235.0%$208.71M$310,000.000.00120BDSXBiodesix2.6834 of 5 stars$1.19-4.0%$3.06+157.1%-16.2%$173.11M$65.56M-3.05220Negative NewsHigh Trading VolumeEUDAEUDA Health0.1736 of 5 stars$4.38+0.9%N/A+284.2%$107.87M$3.81M0.002QIPTQuipt Home Medical3.2162 of 5 stars$2.42-1.2%$6.25+158.3%-51.2%$105.57M$221.74M0.001,200News CoveragePIIIP3 Health Partners3.2506 of 5 stars$0.20-4.7%$2.38+1,065.4%-82.9%$72.90M$1.48B-0.24500Analyst ForecastAnalyst RevisionHigh Trading VolumeENZEnzo Biochem0.5149 of 5 stars$0.99-2.0%N/A-22.3%$52.77M$31.91M0.00520BNRBurning Rock BiotechN/A$4.64+0.9%N/A-48.5%$47.51M$75.70M-0.971,390MRAIMarpai1.994 of 5 stars$1.64+13.1%$6.00+265.9%+80.2%$19.92M$37.15M0.00150CCMConcord Medical Services0.3558 of 5 stars$4.35-3.3%N/A-58.6%$18.88M$75.69M0.00970Gap Up Related Companies and Tools Related Companies LFMD Alternatives SERA Alternatives BDSX Alternatives EUDA Alternatives QIPT Alternatives PIII Alternatives ENZ Alternatives BNR Alternatives MRAI Alternatives CCM Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XGN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
